Inbakicept

Research use only, not for human use.

Inbakicept (ALT 803) is a fusion protein of the IL-15 receptor α-sushi binding domain IL-15RαSu and immunoglobulin G1 (human Fc fragment), which is an IL-15 superagonist protein complex.

Inbakicept, also known as N-803 (Nogapendekin alfa inbakicept), contains the IL-15 cytokine antibody Nogapendekin alfa (HY-P99759). Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation and IFNγ production in cells.

Cell Cytotoxicity Assay Cell Line:Daudi, Raji, CD19+ FL cells Concentration:0.01 nM, 0.1 nM, and 1 nM Incubation Time:20 hours Result:Increased the human NK cell cytotoxicity on Daudi, Raji, CD19+ FL cells.

Animal Model:SCID mice with Daudi models Dosage:0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg Administration:Intravenous injection; twice weekly, for 2 weeks Result:Enhanced rituximab-directed control of Raji lymphoma challenge.

——

Others

Other Targets

Others

——

——

2135939-52-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years